Literature DB >> 8756393

Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats.

V R Muzykantov1, J C Murciano.   

Abstract

Streptavidin-mediated attachment of biotinylated antibodies (b-Ab) to biotinylated red blood cells (b-RBC) is useful for preparation of immuno-red blood cells, a prospective vehicle for drug targeting. However, streptavidin (SA) induces lysis of extensively biotinylated RBC by complement due to cross-linking and inactivation of RBC complement regulators. To reduce cross-linking of RBC membrane proteins, we utilized mild biotinylation of RBC with 20 microM biotin ester (b20-RBC). SA effectively binds to rat b20-RBC (10(5) SA molecules/cell) and provides for following attachment of 5 x 10(4) molecules of b-IgG/SA per b20-RBC. By in vitro assay, b-Ab/SA/b20-RBC were stable in fresh rat serum. Serum-stable immuno-red blood cells (b-Ab/SA/b20-RBC) specifically bound to antigen-coated surfaces, but not to BSA-coated surfaces. Biodistribution of 51Cr-labelled b-Ab/SA/b20-RBC in rats was similar to that of control RBC, with no indication of lysis in vivo. These results suggest b-Ab/SA/b20-RBC may be explored as a vehicle for drug targeting.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756393

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  8 in total

Review 1.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 2.  Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.

Authors:  Carlos H Villa; Douglas B Cines; Don L Siegel; Vladimir Muzykantov
Journal:  Transfus Med Rev       Date:  2016-08-17

Review 3.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

Review 4.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

5.  Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.

Authors:  Sherman C Stein; Kumkum Ganguly; Caitlin M Belfield; Xiangsheng Xu; Edward W Swanson; Xiao-Han Chen; Kevin D Browne; Victoria E Johnson; Douglas H Smith; David G LeBold; Douglas B Cines; Vladimir R Muzykantov; Vladimir R Muzykhantov
Journal:  J Neurotrauma       Date:  2009-09       Impact factor: 5.269

6.  Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.

Authors:  Nai-Jia Huang; Novalia Pishesha; Jean Mukherjee; Sicai Zhang; Rhogerry Deshycka; Valentino Sudaryo; Min Dong; Charles B Shoemaker; Harvey F Lodish
Journal:  Nat Commun       Date:  2017-09-04       Impact factor: 14.919

7.  The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells.

Authors:  Daniel Pan; Omayra Vargas-Morales; Blaine Zern; Aaron C Anselmo; Vivek Gupta; Michael Zakrewsky; Samir Mitragotri; Vladimir Muzykantov
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

Review 8.  Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics.

Authors:  Patrick M Glassman; Carlos H Villa; Anvay Ukidve; Zongmin Zhao; Paige Smith; Samir Mitragotri; Alan J Russell; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Pharmaceutics       Date:  2020-05-09       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.